CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
Cetuximab +1 moredrug
Likely dose
Cetuximab 250mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00350025
NCT00350025Phase 2Completed
CompareCT.gov

Randomized Phase II Trial of Cetuximab With and Without Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer

Fox Chase Cancer Center·interventional·Posted Jul 10, 2006·Updated Mar 31, 2017

In Brief

A Phase 2 clinical trial evaluating Cetuximab and Paclitaxel for Urologic Neoplasm. Completed, enrolled 41 participants across 1 site.

Detailed Summary

The purpose of this research study is to determine whether the investigational drug cetuximab, (Erbitux) alone or with paclitaxel (Taxol) can stabilize the growth of urothelial cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrologic Neoplasm
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 10, 2006
Enrollment StartAug 1, 2006
Primary CompletionJul 1, 2010
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 20.0 years ago

Interventions

Cetuximabdrug

Cetuximab 250mg/m2 IV weekly for each 28 day cycle.

Paclitaxeldrug

Paclitaxel 80mg/m2 IV weekly for each 28 day cycle.